Daniel Chastain is a clinical associate professor at the University of Georgia College of Pharmacy on the Southwest Georgia Clinical Campus and serves as the infectious diseases pharmacist for Phoebe Putney Memorial Hospital in Albany, Georgia.
July 06, 2022
Article
Access to antifungal susceptibility testing (AFST) remains limited in the United States. Therefore, providers must recognize clinical situations where AFST will provide its greatest value. In the latest article from SIDP, infectious disease pharmacists offers some insights on this subject.
FDA Approves Baloxavir Marboxil Flu Drug for Children
New CDC Guidelines Reduce Quarantine After COVID-19 Exposure
Omicron BA.4 and BA.5 Can’t Be Neutralized by Prior Infection
Next Generation Antimalarial MAB Targets Susceptibility of P falciparum